1. Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada 1 .
- Author
-
Langley JM, Gantt S, Quach C, Bettinger JA, Halperin SA, Mutch J, McNeil SA, Ward BJ, MacKinnon-Cameron D, Ye L, Marty K, Scheifele D, Brown E, and Alcantara J
- Subjects
- Adolescent, Adolescent Health Services, Adult, Canada epidemiology, Double-Blind Method, Female, Humans, Immunization Schedule, Male, Universities, Vaccination, Young Adult, Disease Outbreaks prevention & control, Meningococcal Infections prevention & control, Meningococcal Vaccines administration & dosage, Neisseria meningitidis, Serogroup B immunology, Students
- Abstract
Emergency vaccination programs often are needed to control outbreaks of meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) on college campuses. Such campaigns expend multiple campus and public health resources. We conducted a randomized, controlled, multicenter, observer-blinded trial comparing immunogenicity and tolerability of an accelerated vaccine schedule of 0 and 21 days to a longer interval of 0 and 60 days for 4-component MenB vaccine (MenB-4C) in students 17-25 years of age. At day 21 after the first MenB-4C dose, we observed protective human serum bactericidal titers >4 to MenB strains 5/99, H44/76, and NZ 98/254 in 98%-100% of participants. Geometric mean titers increased >22-fold over baseline. At day 180, >95% of participants sustained protective titers regardless of their vaccine schedule. The most common adverse event was injection site pain. An accelerated MenB-4C immunization schedule could be considered for rapid control of campus outbreaks.
- Published
- 2020
- Full Text
- View/download PDF